Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets: 2021-2024

Historic Non-Current Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $248.8 million.

  • Kiniksa Pharmaceuticals International's Non-Current Assets fell 2.95% to $236.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236.8 million, marking a year-over-year decrease of 2.95%. This contributed to the annual value of $248.8 million for FY2024, which is 0.51% down from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Non-Current Assets is $248.8 million, which was down 0.51% from $250.0 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Non-Current Assets ranged from a high of $250.0 million in FY2023 and a low of $36.4 million during FY2021.
  • Moreover, its 3-year median value for Non-Current Assets was $248.8 million (2024), whereas its average is $238.5 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Non-Current Assets surged by 495.84% in 2022, and later fell by 0.51% in 2024.
  • Kiniksa Pharmaceuticals International's Non-Current Assets (Yearly) stood at $36.4 million in 2021, then soared by 495.84% to $216.6 million in 2022, then grew by 15.43% to $250.0 million in 2023, then decreased by 0.51% to $248.8 million in 2024.